Want to see ALXO full AI Analyst Report?
ALXO Stock Chart & Stats
$1.67
$0.01(0.54%)
At close: 4:00 PM EST
$1.67
$0.01(0.54%)
Day’s Range― - ―
52-Week Range$0.44 - $2.66
Previous CloseN/A
Volume579.15K
Average Volume (3M)1.65M
Market Cap
$258.36M
Enterprise Value$82.39
Total Cash (Recent Filing)$140.32M
Total Debt (Recent Filing)$5.22M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding134,562,910
10 Day Avg. Volume1,073,226
30 Day Avg. Volume1,645,899
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.72
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.67Price Target Upside179.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reproducible Biomarker-driven EfficacyIndependent Phase II data showing higher ORR in CD47-high subsets across studies provides durable scientific validation of evorpacept’s MOA. Reproducibility across cohorts reduces biological risk, supports a prospectively selected registrational strategy, and strengthens partner and payer interest.
Large Safety Database And Differentiated MOAA safety database >800 patients and an Fc-engineered design that aims to limit hematologic toxicity materially lower clinical and regulatory risk for a CD47 program. This durable safety evidence supports broader combination use, simplifies regulatory discussions, and improves long-term commercial and partnering prospects.
Strengthened Financing And LeadershipNew financing plus recent senior hires and governance changes increase execution capacity for registrational programs. Extended, milestone-contingent capital and experienced development leadership improve the company’s ability to run complex late-stage trials and engage regulators and partners over the next 12–24 months.
Bears Say
No Revenue And Recurring LossesA development-stage profile with zero commercial revenue and sustained net losses means long-term viability depends on successful clinical readouts or continued external funding. Persistent losses risk equity dilution and constrain strategic optionality if clinical milestones slip.
Weak Cash Generation And Substantial BurnConsistent negative operating and free cash flow forces reliance on financings and lender covenants. This structural cash shortfall can limit investment in registrational trials, create timing pressure around milestones, and raise execution risk if additional capital terms tighten.
Biomarker Uncertainty And Small Sample SizesUnclear CD47 assay thresholds, discordant HER2 testing, and tiny biomarker-positive cohorts mean prospective biomarker validation is required. That creates enrollment, regulatory and label risk, and could limit the addressable patient population absent robust, standardized companion diagnostics.
ALX Oncology Holdings News
ALXO FAQ
What was Alx Oncology Holdings, Inc.’s price range in the past 12 months?
Alx Oncology Holdings, Inc. lowest stock price was $0.44 and its highest was $2.66 in the past 12 months.
What is Alx Oncology Holdings, Inc.’s market cap?
Alx Oncology Holdings, Inc.’s market cap is $258.36M.
When is Alx Oncology Holdings, Inc.’s upcoming earnings report date?
Alx Oncology Holdings, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.
How were Alx Oncology Holdings, Inc.’s earnings last quarter?
Alx Oncology Holdings, Inc. released its earnings results on May 08, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.018.
Is Alx Oncology Holdings, Inc. overvalued?
According to Wall Street analysts Alx Oncology Holdings, Inc.’s price is currently Undervalued.
Does Alx Oncology Holdings, Inc. pay dividends?
Alx Oncology Holdings, Inc. does not currently pay dividends.
What is Alx Oncology Holdings, Inc.’s EPS estimate?
Alx Oncology Holdings, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Alx Oncology Holdings, Inc. have?
Alx Oncology Holdings, Inc. has 134,562,910 shares outstanding.
What happened to Alx Oncology Holdings, Inc.’s price movement after its last earnings report?
Alx Oncology Holdings, Inc. reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 11.23%.
Which hedge fund is a major shareholder of Alx Oncology Holdings, Inc.?
Currently, no hedge funds are holding shares in ALXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ALX Oncology Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.67 (179.44% Upside)
$4.67 (179.44% Upside)
Blogger Sentiment
Neutral
ALXO Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 23.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
279.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
47.50%
Trailing 12-Months
Company Description
Alx Oncology Holdings, Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
ALXO Stock 12 Month Forecast
Average Price Target
$4.67
▲(179.44% Upside)
Technical Analysis
Ownership Overview
10.06% Insiders
3.58% Mutual Funds
55.50% Other Institutional Investors
23.23% Public Companies and
Individual Investors